Germline BRCA-mutated HER2-negative Breast Cancer
Conditions
Brief summary
This study is an open-label, single-arm, multicenter clinical study. 64 patients with germline BRCA-mutated HER2-negative early breast cancer are planned to be enrolled and treated with fluzoparib combined with camrelizumab to observe and evaluate the efficacy and safety of neoadjuvant fluzoparib combined with camrelizumab in the treatment of germline BRCA-mutated HER2-negative early breast cancer。
Interventions
DRUGCamrelizumab+Fluzoparib
Fluzoparib：150mg was given orally twice daily Camrelizumab：200 mg IV drip on Day 1 of each cycle
Sponsors
Peking University People's Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* According to the definition of the latest ASCO/CAP guidelines, early or locally advanced HER2 negative invasive breast cancer confirmed by histopathology meets the following conditions: * HER2 negative: IHC 0/1+or IHC2+with no amplification of ISH; * Primary tumor size: ≥ 1cm * Lymph node status: N0-3 * Inflammatory breast cancer patients with measurable lesions (according to RECIST 1.1 standard) * Patients with bilateral breast cancer whose primary lesions all meet the inclusion criteria, or breast cancer with Tis-1bN0 and HER2 negative on the other side only meeting the inclusion criteria on one side; * The hormone receptor status is known; * ECOG score 0-1; * Carrying BRCA1 or BRCA2 germline pathogenic mutations or suspected pathogenic mutations; * According to RECIST 1.1 standard, at least one measurable lesion is present;
Exclusion criteria
* Tumor related symptoms and treatment * Recurrent or metastatic breast cancer; * Participated in other drug trials or received any anti-tumor therapy, including endocrine therapy, bisphosphate therapy, immunotherapy, biological therapy, or tumor embolization, within 4 weeks prior to enrollment; * Previously received treatment for PD-1/PD-L1 antibodies, CTLA-4 antibodies, or other PD-1/PD-L1 inhibitors; * Previously received PARP inhibitor treatment (excluding those who have completed PARP inhibitor treatment for ovarian cancer for at least 5 years without recurrence or metastasis); * Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS); active hepatitis or combined hepatitis B and C co-infection; autoimmune hepatitis; * Confirmed history of heart failure or systolic dysfunction (LVEF \< 50%); high risk uncontrolled cardiac arrhythmias, such as atrial tachycardia; angina requiring antianginal medication * Female patients who are pregnant or lactating * History of definite neurological or psychiatric disorders, including epilepsy or dementia * Presence of interstitial lung disease, pneumonitis, or uncontrolled systemic disease (eg, diabetes mellitus, pulmonary fibrosis, acute pneumonitis, etc.)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| tpCR（ypT0/is ypN0） | 6 months | total pathological complete response |
Countries
China
Contacts
CONTACTShu Wang, Dr.
CONTACTFei Xie, Dr.
PRINCIPAL_INVESTIGATORShu Wang, Dr.
Breast Center, Peking University People's Hospital
Outcome results
None listed